Pralidoxime rescues both muscarinic and nicotinic systems.
Petroianu
Georg A
GA
Department of Pharmacology & Therapeutics; Faculty of Medicine & Health Sciences; UAE University; United Arab Emirates; georg.petroianu@uaeu.ac.ae.
D000818:Animals; D000931:Antidotes / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D002800:Cholinesterase Inhibitors / Q000378:metabolism / Q000633:toxicity; D002801:Cholinesterase Reactivators / Q000494:pharmacology*; D006801:Humans; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009943:Organophosphorus Compounds / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000633:toxicity; D011220:Pralidoxime Compounds / Q000494:pharmacology*; D011976:Receptors, Muscarinic / Q000187:drug effects*; D011978:Receptors, Nicotinic / Q000187:drug effects*; D013552:Swine; D013556:Swine, Miniature
D000931:Antidotes; D002800:Cholinesterase Inhibitors; D002801:Cholinesterase Reactivators; D018727:Muscarinic Antagonists; D009943:Organophosphorus Compounds; D011220:Pralidoxime Compounds; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic; D001285:Atropine; C028797:pralidoxime